Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Looks like the $900k net from the note is just to cover the annual salaries and bonuses of Dowling and Grasser...Also worth noting is that if there is a change of control, Dowling would get $600k and Grasser would get $470k...
On June 20, 2024, CV Sciences, Inc., a Delaware corporation (the “Company”), entered into a new Executive Employment Agreement (the “Agreement”) with Joseph Dowling, the Company’s current Chief Executive Officer. This Agreement supersedes and replaces the existing Executive Employment Agreement, dated June 23, 2021, as modified per that certain Amendment No. 1 to the Executive Employment Agreement dated January 5, 2023, by and between the Company and Mr. Dowling.
Mr. Dowling will continue to serve as the Company’s Chief Executive Officer pursuant to the terms and conditions of the Agreement. The Agreement has a three-year term and provides for an annual base salary of $300,000 (the “Base Salary”), which amount shall be subject to annual adjustment as approved by the Company's Board of Directors ("Board").
Under the terms of the Agreement, Mr. Dowling is also entitled to receive annual bonuses based on the Company’s performance and/or Mr. Dowling’s performance, subject to approval by the Board. If certain performance goals are met, Mr. Dowling would be entitled to receive a performance bonus, with a target amount of 50% of his then effective Base Salary; provided, however, that the payment and amount of such bonus shall be in the sole discretion of the Board. The Company may also propose new performance goals for purposes of determining additional annual bonuses payable to Mr. Dowling. Mr. Dowling shall also be eligible to participate in the Company’s equity, compensation, and incentive plans as are generally made available to the Company’s management executives; may be eligible to receive incentive stock options or other stock awards under the Company’s 2023 Equity Incentive Plan, as determined by the Board; shall be entitled to a minimum of twenty days of annual paid vacation time exclusive of holidays; and shall be entitled to receive certain other perquisites, as set forth in the Agreement.
In the event the Agreement is terminated upon consummation of a change of control, the Company shall pay Mr. Dowling all salary then due and payable through the date of termination and all unpaid deferred compensation. In addition, the Company shall pay Mr. Dowling a lump sum cash payment equal to two (2) times the Base Salary.
Mr. Grasser will continue to serve as the Company’s Chief Financial Officer pursuant to the terms and conditions of the CFO Agreement. The CFO Agreement has a three-year term and provides for an annual base salary of $235,000 (the “CFO Base Salary”), which amount shall be subject to annual adjustment as approved by the Board.
Under the terms of the Agreement, Mr. Grasser is also entitled to receive annual bonuses based on the Company’s performance and/or Mr. Grasser's performance, subject to approval by the Board. If certain performance goals are met, Mr. Grasser would be entitled to receive a performance bonus, with a target amount of 20% of his then effective CFO Base Salary; provided, however, that the payment and amount of such bonus shall be in the sole discretion of the Company’s Board. The Company may also propose new performance goals for purposes of determining additional annual bonuses payable to Mr. Grasser. Mr. Grasser shall also be eligible to participate in the Company’s equity, compensation, and incentive plans as are generally made available to the Company’s management executives; may be eligible to receive incentive stock options or other stock awards under the Company’s 2023 Equity Incentive Plan, as determined by the Board; shall be entitled to a minimum of twenty days of annual paid vacation time exclusive of holidays; and shall be entitled to receive other perquisites, as set forth in the CFO Agreement.
In the event the CFO Agreement is terminated upon consummation of a change of control, the Company shall pay Mr. Grasser all salary then due and payable through the date of termination and all unpaid deferred compensation. In addition, the Company shall pay Mr. Grasser a lump sum cash payment equal to two (2) times the CFO Base Salary.
Based on the recent 8-k, the current market cap is about 8 times higher than management's own valuation of the company.
Current market cap is $9.5mil, but management put up ALL assets and then some as collateral for a $1,188,500 loan...
"1.5.Security Agreement. The Note shall be secured by the collateral set forth in that certain Security Agreement attached hereto as Exhibit B listing all of Company’s assets as security for Company’s obligations under the Transaction Documents (the “Security Agreement”)."
SCHEDULE A
TO SECURITY AGREEMENT
All right, title, interest, claims and demands of Debtor in and to all of Debtor’s assets owned as of the date hereof and/or acquired by Debtor at any time while the Obligations are still outstanding, including without limitation, the following property:
1.All equity interests in all wholly- or partially-owned subsidiaries of Debtor;
2.All customer accounts, insurance contracts, and clients underlying such insurance contracts;
3.All goods and equipment now owned or hereafter acquired, including, without limitation, all laboratory equipment, computer equipment, office equipment, machinery, fixtures, vehicles, and any interest in any of the foregoing, and all attachments, accessories, accessions, replacements, substitutions, additions, and improvements to any of the foregoing, wherever located;
4.All inventory now owned or hereafter acquired, including, without limitation, all merchandise, raw materials, parts, supplies, packing and shipping materials, work in process and finished products including such inventory as is temporarily out of Debtor’s custody or possession or in transit and including any returns upon any accounts or other proceeds, including insurance proceeds, resulting from the sale or disposition of any of the foregoing and any documents of title representing any of the above, and Debtor’s books relating to any of the foregoing;
5.All accounts receivable, contract rights, general intangibles, healthcare insurance receivables, payment intangibles and commercial tort claims, now owned or hereafter acquired, including, without limitation, all patents, patent rights and patent applications (including without limitation, the inventions and improvements described and claimed therein, and (a) all reissues, divisions, continuations, renewals, extensions and continuations-in-part thereof, (b) all income, royalties, damages, proceeds and payments now and hereafter due or payable under or with respect thereto, including, without limitation, damages and payments for past or future infringements thereof, (c) the right to sue for past, present and future infringements thereof, and (d) all rights corresponding thereto throughout the world), trademarks and service marks (and applications and registrations therefor), inventions, discoveries, copyrights and mask works (and applications and registrations therefor), trade names, trade styles, software and computer programs including source code, trade secrets, methods, published and unpublished works of authorship, processes, know how, drawings, specifications, descriptions, and all memoranda, notes, and records with respect to any research and development, goodwill, license agreements, information, any and all other proprietary rights, franchise agreements, blueprints, drawings, purchase orders, customer lists, route lists, infringements, claims, computer programs, computer disks, computer tapes, literature, reports, catalogs, design rights, income tax refunds, payments of insurance and rights to payment of any kind and whether in tangible or intangible form or contained on magnetic media readable by machine together with all such magnetic media, and all rights corresponding to all of the foregoing throughout the world, now owned and existing or hereafter arising, created or acquired;
6.All now existing and hereafter arising accounts, contract rights, royalties, license rights and all other forms of obligations owing to Debtor arising out of the sale or lease of goods, the licensing of technology or the rendering of services by Debtor (subject, in each case, to the contractual rights of third parties to require funds received by Debtor to be expended in a particular manner), whether or not earned by performance, and any and all credit insurance, guaranties, and other security therefor, as well as all merchandise returned to or reclaimed by Debtor and Debtor’s books relating to any of the foregoing;
7.All documents, cash, deposit accounts, letters of credit, letter of credit rights, supporting obligations, certificates of deposit, instruments, chattel paper, electronic chattel paper, tangible chattel paper and investment property, including, without limitation, all securities, whether certificated or uncertificated, security entitlements, securities accounts, commodity contracts and commodity accounts, and all financial assets held in any securities account or otherwise, wherever located, now owned or hereafter acquired and Debtor’s books relating to the foregoing;
8.All other assets, goods and personal property of Debtor, wherever located, whether tangible or intangible, and whether now owned or hereafter acquired; and
9.Any and all claims, rights and interests in any of the above and all substitutions for, additions and accessions to and proceeds and products thereof, including, without limitation, insurance, condemnation, requisition or similar payments and the proceeds thereof.
I found a recently published research paper that was funded by Charlotte's Web, and I threw in a couple more papers below it as well. The one funded by Charlotte's Web is focused on a new cannabinoid called Cannabielsoin or CBE, (there is S-CBE and R-CBE, this paper focused on S-CBE), which is an oxidation product of CBD. You guys know I love seeing stuff like this...Enjoy!
"Cannabielsoin (CBE), a CBD Oxidation Product, Is a Biased CB1 Agonist":
Published: 12 July 2024
Funding
Funding for this study was provided by Charlotte’s Web.
Results
Histopathological analysis of the LPS group showed moderate hyperemia, hemorrhages, edema, inflammation, and myocardial cell damage. There was a slight to moderate increase in Cox-1, G-CSF, and IL-3 immunoexpressions, along with enhanced expressions of IL-6, Hif1a, and STAT3 genes, and decreased expressions of eNOS genes. Additionally, there were increased levels of TOS and decreased TAS levels observed biochemically. CBD treatment effectively reversed and improved all of these observed changes.
Conclusions
CBD protects the heart and aorta against systemic inflammation through its antioxidant and anti-inflammatory activity via regulating IL-6, Hif1a, STAT3, and eNOS intracellular pathways.
Results: Ninety-seven products were purchased (35 in-store, 62 online). Of the 71 products with a specific total CBD amount on the label, 35 (49%) were underlabeled (>10% more CBD than advertised), 27 (38%) were overlabeled (>10% less CBD than advertised), and 9 (12.7%) were accurately labeled (within ±10% of labeled CBD). The median (range) percentage deviations were -53% (-100%–76%) for haircare products, +18% (-100%-1076%) for cosmetics, and -1% (-100%-4468%) for food/drinks. CBD label accuracy did not differ significantly between products with external testing claims versus those without (t40 = 0.23, p = 0.82). Overall, 24% of the 97 (total) products made a cosmetic or beauty claim (e.g., “skin looks more youthful”), 40% made a therapeutic claim (e.g., “pain relief”), and 86% made a health halo effect claim (e.g., “paraben-free,” “dye-free,” etc.). Most products (63%) did not include a disclaimer that claims had not been evaluated by the FDA.
Conclusions: Most of the products included in this sample were inaccurately labeled for CBD content, including those claiming to have been tested by third party laboratories. A notable finding was that 10 products did not contain any CBD. Many products made therapeutic claims or used marketing tactics to seemingly convey they were safe/healthy, but only about one-third included disclaimers that these statements had not been evaluated by the FDA. These findings highlight the need for proper regulatory oversight of cannabinoid-containing products to ensure quality assurance and deter misleading or unfounded health claims in product marketing.
"Case Report: Cannabis Oil Treats Common Skin Disease in Dog":
JUL 11, 2024
Veterinary students and scientists in Brazil used cannabis oil to successfully treat a dog with a common skin disease that did not respond to previous treatment. The corresponding study was published in Frontiers in Veterinary Science.
Discoid lupus erythematosus (DLE) is a common autoimmune disease that typically affects the skin on the nose and ears of dogs. It is characterized by inflammation, loss of hair pigment, and redness, which can lead to crusting and ulceration. The condition's underlying cause remains unknown; however, it is thought to arise from a mix of genetics, infections, hormones, and sun exposure. Current treatments include corticosteroids to reduce inflammation; however, these carry a risk of unwanted side effects.
Previous research suggests that cannabinoids cannabidiol (CBD) and tetrahydrocnnabidiol (THC) reduce inflammation in both dogs and humans without any detrimental side effects.
In the current case report, a two-year-old female mixed-breed dog with DLE was not responding to corticosteroids and other medications. The researchers thus decided to treat the dog with cannabis oil.
After some experimentation, they found that cannabis oil containing CBD and THC on a ratio of 3:1 worked best. To begin, the dog was given a single drop orally once daily for three days to test for negative reactions. The treatment continued after no negative reactions were reported, and the dosage was slowly adjusted until the minimum effective dose was found. After several weeks, some signs of DLE started to disappear, and after a year, all symptoms were relieved.
"After 1year, the dog remains clinically stable on a low dose of full-spectrum CBD-rich oil. No evidence of DLE recurrence was observed," wrote the researchers in their paper.
“This case suggests that cannabinoid therapy (CT) may be a viable alternative or complementary therapy for DLE in dogs, particularly for those experiencing adverse effects from conventional treatments. Further research is warranted to confirm the efficacy and safety of CT for DLE management in dogs,” continued the researchers.
Here's an article that gets into more specifics...
"How the Supreme Court Overturning a Case Against Chevron Oil Threw the Marijuana Industry into Chaos":
Jul 8, 2024
For instance, if a federal agency says a product can't contain a certain amount of CBD, companies can more easily challenge that decision in court. The agency can no longer rely solely on its supposed expertise to defend its rules.
Yeah, there's always that question of when. Maybe the Chevron ruling will combine with rescheduling to make schedule 3 even more meaningful to companies. At the very least, companies soon won't have to remove every molecule of THC to gain FDA approval...
"Cannabis Medications Could Be Eligible For FDA Approval Under Proposed DEA Rules":
July 8, 2024
The US Drug Enforcement Administration has proposed new rules that mean, for the first time, medications containing delta-9 THC from the cannabis plant could be eligible for approval by the US Food and Drug Administration (FDA).
"Supreme Court’s Chevron Doctrine Ruling Could Limit FDA’s Regulatory Authority":
Jul 01, 2024
In overruling Chevron on Friday, the Supreme Court ushered in a new framework, dubbed Loper Bright. Courts are now required to “exercise their independent judgement in deciding whether an agency has acted within its statutory authority” and “may not defer to an agency interpretation of the law simply because a statute is ambiguous.”
This new framework could have significant consequences for the FDA and its regulatory authority, according to an analysis by global law firm Sidley.
The firm contends that Loper Bright could potentially open the regulator’s drug approvals to legal challenges. Companies need to provide “substantial evidence” that their drug candidates are safe and effective before securing approval, but courts in the past have found this ambiguous and have allowed the FDA to ask for additional requirements, such as data showing that the candidate’s effects are clinically meaningful, according to Sidley.
Under Loper Bright, more companies could try and challenge this approach, Sidley warned.
The overturning of Chevron could also pose some jurisdictional questions for the FDA, which is typically given the leeway to decide what constitutes a dietary supplement or a device product. These kinds of determinations affect how products are regulated, produced, or imported—and companies can now mount stronger challenges to this function by the FDA.
FYI-"The FDA’s power to determine a drug’s exclusivity or review tobacco marketing applications faces fresh vulnerability to legal battles after the Supreme Court’s decision to nix a legal doctrine that empowered agency interpretations.
The US Supreme Court’s June 28 opinion in Loper Bright Enters. v. Raimondo is expected to open the floodgates for litigation against the Food and Drug Administration after ending the decades-old Chevron doctrine. Under the 1984 decision in Chevron v. Natural Resources Defense Council, courts had accepted a federal agency’s reasonable interpretation of its rulemaking authority when its statute was determined ambiguous."
https://news.bloomberglaw.com/health-law-and-business/fda-drug-approvals-rulemaking-are-tested-after-chevron-decision
The "Autism" trend chart is even more shocking than the earlier chart for ASD, "Autism Spectrum Disorder"...
Does anyone have any politically correct explanations for this chart?...
"Autism"
https://trends.google.com/trends/explore?date=all&geo=US&q=%2Fg%2F121kwpxw&hl=en-US
That ASD trend chart shocked me. It should be on the news.
"Could an NLRP3 inhibitor be the one drug to conquer common diseases?":
February 17, 2020
https://cen.acs.org/pharmaceuticals/drug-discovery/Could-an-NLRP3-inhibitor-be-the-one-drug-to-conquer-common-diseases/98/i7
CBD's range of powers should make more sense now...
"Pharma Looks to Inflammasome Inhibitors as All-Around Therapies":
Apr 1, 2021
Many major biopharmaceutical companies are developing or acquiring drugs that target the NLRP3 inflammasome, a large intracellular complex that researchers say can spark inflammation and stoke diseases of lifestyle and aging.
https://www.the-scientist.com/pharma-looks-to-inflammasome-inhibitors-as-all-around-therapies-68582
"...finding drugs to selectively stop NLRP3 will be difficult."
https://cen.acs.org/pharmaceuticals/drug-discovery/Could-an-NLRP3-inhibitor-be-the-one-drug-to-conquer-common-diseases/98/i7
"...we emphasize the capacity of cannabidiol to suppress inflammation by blocking the NLRP3 signaling pathway..."
https://link.springer.com/article/10.1007/s00011-023-01831-y
Recreate+MLB+PLL website looking good...
https://recreateyou.com/mlb
https://recreateyou.com/pll
"Farmers, businesses push back on Florida Republicans' efforts to restrict THC products"
Feb 16, 2024
https://www.orlandoweekly.com/cannabis/farmers-businesses-push-back-on-florida-republicans-efforts-to-restrict-thc-products-36201768
Same goes for ASD..."Multiple inflammasome complexes are activated in autistic spectrum disorders":
2016 Mar 12
Abstract
Background: Inflammasomes are multimeric protein platforms involved in the regulation of inflammatory responses whose activity results in the production of proinflammatory cytokines. Because neuroinflammation is observed in autistic spectrum disorders (ASD), a neurologic condition of childhood resulting in a complex behavioural impairment, we analyzed the inflammasomes activity in ASD. Additionally we verified whether alterations of the gastrointestinal (GI) barriers might play a role in inflammasomes activation.
Methods: The activity of the inflammasomes, the concentration of the inflammasomes-derived proinflammatory cytokines interleukin (IL)-1ß and IL-18, and serum parameters of GI damage were analyzed in 25 ASD children, 23 healthy siblings (HS) and 30 unrelated age-matched healthy controls (HC).
Results: A significant upregulation of the AIM2 and the NLRP3 inflammasomes and an increased production of IL-1ß and IL-18 that was associated with a consistent reduction of IL-33, an anti inflammation cytokine were observed in ASD alone. Notably, in a possible immune-mediated attempt to dampen inflammation, IL-37, a suppressor of innate inflammatory responses, was significantly augmented in these same children. Finally, intestinal fatty acid binding protein (IFABP), an index of altered GI permeability, was significantly increased in serum of ASD and HS.
Conclusions: These results show that the inflammasomes are activated in ASD and shed light on the molecular mechanisms responsible for ASD-associated neuroinflammation. The observation that GI alterations could be present as well in ASD offers a possible link between such alterations and neuroinflammation. Therapeutic strategies targeting inflammasome activation could be useful in ASD.
"Inflammasomes"...Looks like we're on to something here...CBD/Hemp extract has shown promise for all of these conditions as well...
"...Inflammasome Activation Is Pathogenic in Multiple Neurological Diseases":
Feb. 14, 2024
This article provides increasing evidence that activation of several types of inflammasomes and extracellular ASC specks contribute to the development and progression of multiple neurological diseases including Alzheimer’s disease (AD), Parkinson’s disease (PD), multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), epilepsy, traumatic brain injury (TBI), and stroke.
Many neurological conditions involve an underlying chronic inflammasome-mediated inflammatory process that worsens the trajectory of these conditions.
Beyond NLRP3, evidence suggests that other inflammasomes, including but not restricted to NLRP1, NLRC4, and AIM2, and their downstream effectors contribute to neuropathology in AD, PD, ALS, MS, stroke, epilepsy, and TBI.
Re: Social benefit projects...I was happy with what these guys were doing with Realm of Caring and thought they would do more together. Maybe the FDA would pick on them for it now. I don't know, but I do think CW should do all, most, or at least some of their social benefit work through RoC. It made more sense IMO.
The jabs could use a sprinkle of CBD to tone down the pericarditis a bit...
"Cannabidiol Formulation Granted Orphan Drug Designation for Pericarditis"
February 15, 2024
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=173861656
Well, whaddya know. FDA grants orphan drug status for a CBD formulation to protect from a very popular "vaccine" side effect, based on the NLRP3 inflammasome I posted about a couple weeks ago..."Cannabidiol Formulation Granted Orphan Drug Designation for Pericarditis":
February 15, 2024
The Food and Drug Administration (FDA) has granted Orphan Drug designation to CardiolRx™ (cannabidiol oral solution) for the treatment of recurrent pericarditis. The NLRP3 inflammasome is known to play a key role in the inflammation and fibrosis associated with pericarditis.
"Why to consider botanical drug INDs?":
Dietary supplements:
-Cannot make medical claims: dietary supplements are restricted from making medical claims, limiting their market positioning.
-Low market barrier and high competition
-High product development cost leading to low-profit margin
What a botanical drug IND provides:
-A botanical drug IND allows you to make distinct medical claims, creating a market barrier
-Botanical drugs are not required to show specific active ingredients.
-Botanical drugs can be developed from a single plant or a blend of multiple plants, providing flexibility in product development.
-No need to describe the mechanism of action
-The success rate is significantly higher when developing known safe and effective botanical products compared to synthesizing or purifying new chemical molecules.
-The concept of botanical drugs primarily exists within the FDA regulatory framework and is specific to the process of regulatory filing and approval. Once botanical products receive approval as prescription drugs and enter the market, there is no perceived difference from chemical drugs.
"Botanical Drug Development Guidance for Industry":
https://www.fda.gov/media/93113/download
Fwiw, I was happy to see the CEO of Ben and Jerry's in the picture at all as I sent the company an email suggesting they work with Ben and Jerry's years ago. I meant something more like a business venture though and not just another board member as I think this company has had way too many execs and board members passing through already. They need permanent long term people who are dedicated to the bigger long term goals. Hopefully, something bigger can come out of them working together. I saw he took no shares when he joined the Board, which is different than usual...
https://www.otcmarkets.com/filing/html?id=17247304&guid=5Qd-kKhdNG6Vvhh
I am aware of the very real effect of full spectrum hemp extract on Autism and I think that should be one of the best and most widespread uses for it. I am still waiting for an autistic spectrum relative's federal legal situation(drug tests) to finish up after many years so they can try it for the first time. I think it could be a life changer for them. My pessimism here comes only from the business side, not the science side at all.
I also am not a fan of corporate America's version of "social equity". "Get woke, go broke" is a well known saying now for a reason. I'd like to see CW drop the B corp designation, donate to an appropriate charity when it makes sense, and stop giving away money, products, and company IP based on sexual preference and skin color. Corporate wokeness is just racism and bigotry and was supposed to be illegal in America. I grew up in a genuinely multicutural way, in one of the most multicultural neighborhoods in America, with friends and girlfriends of all races, so the fake woke shit is just nails on a chalk board to me. Gay people are not victims who deserve free money just because they are gay and it's not ok to give away shareholder IP to farmers just because they are Black farmers and not White or Asian farmers.
I honestly can't believe I've found my self explaining this stuff to adults who run million or billion dollar corporations in 2024, but here we are, that's our country now, a confused cult. I never expected Big Tobacco to be involved here, and am surprised I stuck around after they showed up. However, if they can stick to CW's original mission, I am all for their redemption. This company's social goals were originally supposed to be about disabled children and adults who lacked access to the plant. That is a mission I can respect. Those people really do need the products and support. I wont be lead astray like the kids today though into cheering for a social philosophy that I know is the exact opposite direction of where the country was headed 15-25 years ago, when we were much more on the right track. I want to see the original mission succeed and will criticize deviation from that, especially when it is morally bankrupt and detrimental to shareholders.
???...
Select symbol
Canada
CWEB:TORTSX
United States
CWBHF:QXEOTCQX International
Germany
6CW:FRAFrankfurt Stock Exchange
6CW:DEUGerman Composite
6CW:DUSDusseldorf Stock Exchange
6CW:BERBerlin Stock Exchange
6CW:MUNMunich Stock Exchange
6CW:STUStuttgart Stock Exchange
On April 6, 2023, the Company announced the formation of DeFloria LLC, a Delaware limited liability company (“DeFloria”) with AJNA BioSciences PBC (“AJNA”), and a subsidiary of British American Tobacco PLC (LSE: BATS and NYSE: BTI) (“BAT”). BAT holds a 100% equity interest in the preferred units of DeFloria and the Company and AJNA each hold 50% of the joint venture’s voting common units. The Company’s contribution to the joint venture was a license permitting the use of certain proprietary hemp intellectual properties, including clinical and consumer data.
Effective February 12, 2024, the Company and DeFloria entered into a Master Services Agreement (“Services Agreement”) pursuant to which the Company will be compensated for the provision of certain services to DeFloria. The services include assistance with Standard Operating Procedures (SOPs), product testing, stability testing, lab liaison, sampling of product, sample submission, data review, Out of Specification (OOS) evaluation, BMCS, document creation, documentation transition project, BR review, spec/RF creation, clinical trials advisory, OOS and risk mitigation testing.
New 8-K...not sure why the big drop...
https://www.otcmarkets.com/filing/html?id=17276969&guid=8dd-keHwt05eJth
"Black⬛️Rock and Fidelity Continue to Lead Spot BTC ETF Inflows"...
4 hours ago
https://www.coinspeaker.com/bitcoin-52k-spot-btc-etf-inflows/
Maybe Satoshi=Black⬛️Rock.
You got it MG. Apparently, it is kind of old news, but it's new to me. Venmo customer service was shocked about it when I asked them, as if they had never heard of it before. They said they would email back a response and confirmation of our phone discussion and never got back to me at all...what to do next???...
"Why Venmo sent my personal info – and yours – to Braze":
Feb 24, 2020
https://www.usatoday.com/story/tech/2020/02/24/why-okcupid-venmo-grindr-send-braze-personal-info/4845495002/
Lyrica vs CBD for PTSD...
"CBD=#9 most effective"
"Lyrica=#62 most effective"
https://www.stuffthatworks.health/complex-post-traumatic-stress-disorder-c-ptsd/compare-treatments/cannabidiol-vs-pregabalin
Lyrica(Pregabalin) vs Cannabidiol(CBD) for Epilepsy...
Lyrica="#27 Most Tried, #24 Most Effective, #15 Most Detrimental"
"REPORTED SIDE EFFECTS
10%Weight gain
6%Drowsiness
6%Fatigue"
https://www.stuffthatworks.health/epilepsy/treatments/pregabalin
CBD="#13 Most Tried, #14 Most Effective"
"REPORTED SIDE EFFECTS
2%Drowsiness
1%Fatigue
0.7%Weight gain"
https://www.stuffthatworks.health/epilepsy/treatments/cannabidiol
Yeah crazy times we live in.
Fwiw, other trackers in other financial apps like CashApp have also been blocked. Bugsnag and Optimizely are two other examples. Braze however was trying to get more specific info like first name, last name, gps coordinates, email address, city, and like 20 more categories.
I caught this company extracting personally identifying info from my phone through Venmo this past weekend. I had never heard of Braze until I saw 39 tracking attempts of theirs blocked from my phone. I'd like to uninstall Venmo now, but can't just yet. It just doesn't seem appropriate for a financial/banking app.
https://www.braze.com/
SEC, CCP, ETH...and gary...
"Former Ethereum Advisor Steven Nerayoff Accuses SEC Chair of Undisclosed ETH Involvement":
February 13, 2024
Additionally, reports from TruthLabs indicate the CCP may control over 66.6% of the ETH supply.